Murphy B R, Collins P L, Lawrence L, Zubak J, Chanock R M, Prince G A
Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, Bethesda, Maryland 20892.
J Gen Virol. 1989 Aug;70 ( Pt 8):2185-90. doi: 10.1099/0022-1317-70-8-2185.
Immunization strategies to prevent respiratory syncytial virus (RSV) disease will involve immunization of infants less than 2 months of age who possess maternally derived RSV antibodies. Vaccinia-RSV recombinant viruses are useful tools for defining parameters important in immunization against RSV and also are being considered as live virus vaccines for use in humans. Previous studies demonstrated that passively acquired RSV antibodies can suppress the immune response and the protective efficacy of vaccinia-RSV recombinants administered by the intradermal route. The present study demonstrates that the suppressive effects of passively acquired antibody on immunity induced by intradermally administered vaccinia-RSV recombinants in cotton rats can be partially overcome by administration of the recombinants by the intranasal route.
预防呼吸道合胞病毒（RSV）疾病的免疫策略将涉及对小于2个月龄且具有母源RSV抗体的婴儿进行免疫接种。痘苗-RSV重组病毒是确定RSV免疫接种重要参数的有用工具，也被视为用于人类的活病毒疫苗。先前的研究表明，被动获得的RSV抗体可抑制经皮内途径接种的痘苗-RSV重组体的免疫反应和保护效力。本研究表明，通过鼻内途径接种重组体可部分克服被动获得的抗体对棉鼠经皮内接种痘苗-RSV重组体诱导的免疫的抑制作用。
